EMA’s EUSTART explained: what the new pre-submission meeting means for your MAA

What does EUSTART mean for sponsors preparing an EU MAA? The new EU Submission, Timelines and Review Talk (EUSTART) aims to help applicants prepare for joint pre-submission meetings with EMA, rapporteurs and national competent authorities ahead of marketing authorisation applications (MAAs).
EMA’s ePI guidance for centralised procedures: what applicants need to know

What does EMA’s ePI guidance mean for sponsors submitting product information? Learn how you might be affected by the European Medicines Agency guidance for applicants submitting electronic product information (ePI) in centralised procedures.
Medicine shortages: Why manufacturing is only part of the solution

In a recent interview with Swedish healthcare publication Dagens Medicin, Nelly Fransén, Expert Regulatory Affairs and specialist in pharmaceutical formulation, discussed the practical and regulatory considerations involved in producing pharmacy-compounded alternatives to transdermal oestrogen medicines in Sweden. In this article, she shares further insights into the complexity of solving medicine shortages.
Signs of optimism at Nordic Life Science Days

NLSDays 2026 brought the Nordic life science community together in Stockholm for two days of conversations, knowledge sharing and new connections. Arex Advisor CEO Linda Thunell shares some of her reflections through a regulatory affairs lens.
Biosimilar development – Scientific advances behind new EMA guidance

The rapid evolution of biosimilar regulation over the past decade is reflected in EMA’s Concept paper proposing a revision of the Guideline on Similar Biological Medicinal Products, which was last revised in 2015. EMA states that the revision is needed because “major progress has been made in the analytical sciences and regulatory field of biosimilars”.
2025 CMDh Activities – What matters for industry stakeholders?

In November 2025 the Coordination Group for Mutual Recognition and Decentralised Procedures – human (CMDh) celebrated its 20th anniversary, reflecting on achievements so far, and future challenges. CMDh has summarized this event and their other activities in 2025.
CMDh – the road ahead to 2028

The Coordination Group for Mutual Recognition and Decentralised Procedures – human (CMDh) has recently published its Multi-annual Workplan to 2028 , outlining its priorities across four main areas.
EMA to strengthen the PRIME scheme with three new features

On 18 March 2026, the European Medicines Agency (EMA) published its plans to implement three new PRIME scheme features following a successful two-year pilot. These 3 new pilot features had been launched in April 2023 to fulfil recommendations for improvement of the PRIority Medicines (PRIME) scheme.
Whitepaper: European Biotech Act – Regulatory impact and implications for sponsors

This whitepaper provides a clear and concise overview of the Act’s background, intent, and the key pieces of regulatory legislation it is set to influence.
EU pharma legislation reform – implications for orphan medicines

This article focuses on the impact of this EU pharma legislation reform with regards to orphan medicinal products.